Core Viewpoint - A-share listed companies are actively engaging in shareholder return activities, utilizing methods beyond cash dividends, such as offering products, services, discount coupons, or exclusive rights, with mixed market performance but overall outpacing the CSI 300 index [1] Group 1: Shareholder Return Activities - Approximately 130 companies have shown varied market performance, with some adopting creative ways to reward shareholders [1] - Companies are not only providing gifts but are also formulating future dividend plans, with 10 companies announcing shareholder return strategies for the next three years [1] Group 2: Dividend Plans and Performance - The top performers in terms of stock price increase since 2025 include Haoen Qidian (301488) with a rise of 205.66%, Shuiyang Co. (300740) at 87.59%, and Huasheng Co. (600156) at 69.18% [3] - Specific dividend plans include: - Haoen Qidian: Minimum 10% of distributable profit annually from 2025 to 2027 [3] - Shuiyang Co.: Cash dividends not less than 10% of distributable profit annually from 2025 to 2027 [3] - Huasheng Co.: Cumulative cash distribution of at least 30% of the average distributable profit over the last three years from 2026 to 2028 [3] - Other companies like Gais Food (36.36%) and Bona Film (34.26%) also have significant dividend commitments [3]

Core Viewpoint - He Eye Hospital is focusing on the strategic goal of "Smart Bright City" by building an "Internet + Healthcare" full lifecycle eye health management platform [2] Group 1: Business Development - The company has integrated intelligent diagnostic systems and established an intelligent imaging cloud platform for ophthalmology [2] - He Eye Hospital has developed a multimodal data fusion decision-making system leveraging deep learning algorithms for health management [2] Group 2: Product Innovations - The "He Diabetes Manager" combines dynamic blood glucose monitoring devices to provide real-time blood sugar level monitoring, enabling precise blood sugar control and eye disease prevention for diabetes patients [2] - The "Bright House" utilizes smart ophthalmic equipment as an entry point, integrating online and offline diagnosis and treatment systems to screen for eye diseases and related chronic conditions [2] Group 3: Impact on Business Performance - Currently, these initiatives have not significantly impacted the company's main business and performance, but the company will fulfill information disclosure obligations if there are major developments [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 重要提示： 1.本次股东会无增加、变更、否决提案的情况。 2.本次股东会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2026年第一次临时股东会于2026年1月14日召 开，公司董事会已于2025年12月25日在巨潮资讯网上刊登了《关于召开2026年第一次临时股东会的通 知》。 本次股东会由公司董事会召集，现场会议由公司董事长何伟先生主持，会议召开符合《公司法》《上市 公司股东会规则》《深圳证券交易所创业板股票上市规则》及《公司章程》等规定。 1.会议召开方式：本次股东会采用现场和网络投票相结合的方式召开。 2.会议召开日期和时间： 出席本次股东会的股东及其股东代表均为2026年1月7日（星期三）下午深圳证券交易所收市时，在中国 证券登记结算有限责任公司深圳分公司登记在册的公司普通股股东。 （1）股东出席的总体情况 通过现场和网络投票的股东84人，代表股份87,746,065股，占公司有表决权股份总 ...

证券日报网讯 1月14日，何氏眼科发布公告称，公司2026年第一次临时股东会审议通过《关于补选公司 第三届董事会非独立董事的议案》《关于制定的议案》。 （文章来源：证券日报） ...

北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2026 年第一次临时股东会的 法律意见书 $$\bumpeq\mathbf{O}\,\bumpeq\,\mathbf{\hat{\nabla}}\,\mathbf{\hat{\nabla}}\,\mathbf{\hat{F}}\,\bumpeq\,\mathbf{\hat{\nabla}}$$ 1 法律意见书 北京市中伦律师事务所 在本法律意见书中，本所律师仅对本次股东会的召集、召开程序、出席会议 人员的资格、召集人资格及会议表决程序、表决结果是否符合《公司法》《股东 会规则》等法律、法规、规范性文件及《公司章程》的规定发表意见，不对会议 关于辽宁何氏眼科医院集团股份有限公司 2026 年第一次临时股东会的 法律意见书 致：辽宁何氏眼科医院集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受辽宁何氏眼科医院集团股 份有限公司（以下简称"公司"）委托，指派本所律师对公司 2026 年第一次临时 股东会（以下简称"本次股东会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 中国证券监督 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次股东会无增加、变更、否决提案的情况。 证券代码：301103 证券简称：何氏眼科 公告编号：2026-001 辽宁何氏眼科医院集团股份有限公司 2026 年第一次临时股东会决议公告 2.本次股东会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2026 年第一次临 时股东会于 2026 年 1 月 14 日召开，公司董事会已于 2025 年 12 月 25 日在巨潮 资讯网上刊登了《关于召开 2026 年第一次临时股东会的通知》。 本次股东会由公司董事会召集，现场会议由公司董事长何伟先生主持，会议 召开符合《公司法》《上市公司股东会规则》《深圳证券交易所创业板股票上市规 则》及《公司章程》等规定。 1.会议召开方式：本次股东会采用现场和网络投票相结合的方式召开。 2.会议召开日期和时间： 现场会议时间为：2026 年 1 月 14 日（星期三）14:00 网络投票时间为：2026 年 1 月 14 日（星期三） 其中，通过深圳证券 ...

Group 1 - The core viewpoint of the articles highlights He Eye Hospital's recent membership in the National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance, which aims to enhance clinical applications of AI in healthcare and improve diagnostic capabilities [1] - He Eye Hospital plans to leverage the alliance's resources to deepen international cooperation in research and development, focusing on the application of AI in screening various eye diseases [1] - The establishment of the AI sub-alliance on January 4, 2025, has already attracted over 100 member units, promoting the integration of high-quality medical resources into grassroots healthcare services [1] Group 2 - He Eye Hospital is positioned as a digital eye health ecosystem group, aiming to create a "Smart Bright City" by collaborating with institutions like Liaoning He Medical College and He Eye Industry Group [2] - The company is focusing on eye health, anti-aging, and longevity technologies, integrating big data, AI, and genetic technologies to develop a new model for comprehensive eye health and chronic disease management [2] - In terms of intelligent applications, He Eye Hospital has developed an intelligent diagnostic system and a specialized imaging cloud platform, utilizing deep learning algorithms for health management [2] Group 3 - He Eye Hospital is also working to promote China's eye care technologies and experiences internationally, through talent training and technology sharing, aiming to enhance local eye health service capabilities in other countries [3] - The company seeks to provide replicable and sustainable models for smart eye health ecosystems, based on innovative screening technologies and management practices [3]

Core Insights - He Eye Hospital has officially become a member of the National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance, enhancing its integration into a national-level innovative platform for smart healthcare and AI clinical applications [1][2] - The National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance was established on January 4, 2025, with over 100 member units currently [1] - He Eye Hospital aims to create a "Smart Light City" by collaborating with various institutions, focusing on eye health, anti-aging, and longevity technology, utilizing new technologies such as big data, AI, and stem cells [1][2] Industry Developments - In the field of ophthalmic intelligent applications, He Eye Hospital has developed an intelligent auxiliary diagnostic system and an ophthalmic specialty imaging cloud platform, leveraging deep learning algorithms for health management [2] - The "He Diabetes Manager" integrates dynamic blood glucose monitoring to provide personalized health management solutions for diabetes patients, ensuring precise blood sugar control and eye disease prevention throughout their life cycle [2] - The "Bright House" initiative utilizes smart ophthalmic equipment to screen for eye diseases and related chronic conditions, creating a digitally empowered grassroots eye health management scenario [2] International Collaboration - He Eye Hospital is actively responding to the Belt and Road Initiative by collaborating with partners to promote China's eye care technology and experience internationally [2] - The hospital aims to enhance local grassroots eye health service capabilities in Belt and Road countries through talent training, technology sharing, and the establishment of blindness prevention models [2] - The membership in the National Ophthalmology Alliance's Artificial Intelligence Sub-Alliance will facilitate deeper international cooperation in research and development, expanding AI applications in ophthalmic disease screening [2]

Group 1 - The core viewpoint of the news is that He Eye Hospital has officially become a member of the National Ophthalmology Alliance Artificial Intelligence Sub-Alliance, enhancing its integration into a national-level innovative platform for smart healthcare and AI clinical applications [1] - The National Ophthalmology Alliance Artificial Intelligence Sub-Alliance was established on January 4, 2025, with over 100 member units, aiming to promote the development of AI technology in ophthalmology and improve access to quality eye health services [1] - He Eye Hospital aims to build a "Smart Bright City" by collaborating with various institutions, focusing on eye health, anti-aging, and longevity technology, integrating new technologies such as big data, AI, and stem cells [1] Group 2 - He Eye Hospital has developed an intelligent auxiliary diagnosis system and an ophthalmology specialty intelligent imaging cloud platform, utilizing deep learning algorithms for health management [2] - The "He Diabetes Manager" combines dynamic blood glucose monitoring to achieve precise blood sugar control and eye disease prevention for diabetes patients throughout their life cycle [2] - He Eye Hospital is actively responding to the Belt and Road Initiative by promoting Chinese ophthalmic blindness prevention technology and experience internationally, enhancing local eye health service capabilities in partner countries [2] Group 3 - He Eye Hospital plans to leverage its membership in the National Ophthalmology Alliance Artificial Intelligence Sub-Alliance to deepen international cooperation in research and application of AI in ophthalmology, contributing to the health of the broader community [3]

截至2026年1月12日收盘，何氏眼科(301103)报收于20.84元，上涨2.86%，换手率1.99%，成交量3.14万 手，成交额6458.06万元。 董秘最新回复 投资者： 请问何星儒何总，贵公司股价长期处于低位，对公司品牌带来极大负面影响，为何不积极回 购股份提升公司的市场价值呢？ 董秘： 尊敬的投资者您好，截止目前公司已累计回购股份2,722,719股。关于股份回购计划，公司管理 层将根据公司资金安排并结合实际经营情况及未来发展需求等多种因素考量，未来如有回购相关计划， 将严格按照法律法规及交易所规则，履行决策程序并及时披露相关信息。公司将继续做好经营管理，夯 实企业内在价值，坚持长期可持续发展战略、透明的信息披露与有效的投资者沟通，稳步推进资本市场 品牌建设，努力为投资者创造长期价值。谢谢！ 投资者： 董秘你好，公司长期大幅破发，投资者毫无获得感，作为辽宁地区知名企业，后续公司有什 么具体的稳定提升股价的措施吗？ 董秘： 尊敬的投资者您好，股价的波动受市场整体情绪、行业板块轮动、资金偏好等多重因素综合影 响。公司坚持聚焦主业，稳健经营，以投资者为本，通过不断完善公司治理，积极加强与国内外同领域 ...